Get Premium to unlock powerful stock data

INNOVAGE ALERT: Bragar Eagel & Squire, P.C. Is Investigating InnovAge on Behalf of InnovAge Stockholders and Encourages Investors to Contact the Firm

Author's Avatar
Business Wire
Sep 25, 2021
Article's Main Image

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against InnovAge Holding Corp. (“InnovAge” or the “Company”) (NASDAQ: INNV) on behalf of InnovAgestockholders. Our investigation concerns whether InnovAge has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On September 21, 2021, after the market closed, InnovAge revealed that the Centers for Medicare and Medicaid Services (“CMS”) had “determined to freeze new enrollments at [the Company’s] Sacramento center based on deficiencies detected in [a recent] audit.” The Company stated that these “deficiencies relate to failures to provide covered services, provide accessible and adequate services, manage participants’ medical situations, and oversee use of specialists, among others.”

On this news, the Company’s stock price fell $2.90, or nearly 25%, to close at $8.75 per share on September 22, 2021, thereby injuring investors.

If you purchased or otherwise acquired InnovAge shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling+out+this+contact+form. There is no cost or obligation to you.

CT?id=bwnews&sty=20210924005563r1&sid=txguf&distro=ftp

View source version on businesswire.com: https://www.businesswire.com/news/home/20210924005563/en/

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
Rating:
NaN / 5 ( votes)

Please Login to leave a comment